|By Marketwired .||
|November 26, 2012 10:51 AM EST||
NEW YORK, NY -- (Marketwire) -- 11/26/12 -- Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) has today announced that Immunovative Therapies, Ltd. ("ITL") has secured the grant of United States Letters Patent ("U.S. Patent") entitled "METHOD FOR STIMULATING A THERAPEUTIC IMMUNE EFFECT IN A PATIENT," which was issued October 20, 2012, under Patent No. 8,298,587. Foreign versions of this patent are still pending around the world. This is the 12th U.S. patent issued to ITL covering its lead biological drug candidate called AlloStim with additional patents still pending. The next product in the pipeline, AlloVax, is an individualized anti-cancer vaccine which combines AlloStim with chaperone proteins called "CRCL." CRCL technology, in-licensed from the University of Arizona and is covered by US Patent No. 6,875,849 entitled "Methods of recovering chaperone proteins and complexes thereof." Therefore, ITL currently has 13 issued US patents with additional patents pending worldwide.
This newly issued patent broadly covers our lead drug candidate called AlloStim, which completed a 42 patient Phase I/II human trial in May 2010. Previously, the Company announced patents issued to cover AlloStim as a composition of matter. This newly issued patent covers AlloStim as a method for preparing cells for patient treatment. The claims cover the infusion of immune T-cells derived from a donor other than the patient that have cross-linked surface molecules called CD3 and CD28. AlloStim is a living cell immunotherapy product that is designed to elicit our proprietary anti-cancer mechanism called the "Mirror Effect." The Mirror Effect enables the stimulation of the same powerful anti-tumor mechanism of allogeneic stem cell and bone marrow transplant procedures, called the graft vs. tumor (GVT) effect, without the toxic side-effect called graft vs. host disease (GVHD). The GVT mechanism has been described as the most powerful anti-tumor mechanism ever discovered because it is capable of killing chemotherapy-resistant metastatic tumors. The clinical application of GVT is limited to certain type of blood cancers due to GVHD toxicity. The Mirror Effect is the first mechanism to be discovered that enables the GVT effect without GVHD toxicity.
AlloStim is designed to elicit the Mirror Effect in cancer patients by stimulating the patient's immune system to eliminate tumor cells wherever they reside in the body. The cross-linking of the CD3 and CD28 surface molecules on AlloStim cells is a critical step in the process for eliciting the Mirror Effect. This newly issued patent protects the concept of cross-linking CD3 and CD28 on any type of T-cell derived from any donor other than the patient.
Seth M. Shaw, CEO of IMUN, stated: "Our growing patent portfolio with broad claim coverage of the Mirror Effect mechanism and our lead AlloStim product provides us with a platform technology for developing a pipeline of new immunotherapy drugs targeted against all types of cancers and viral diseases. This patent protection provides us with the unprecedented opportunity to develop and pioneer a new immunotherapy industry."
Dr. Michael Har-Noy, CEO, founder of ITL and inventor of the "Mirror Effect" technology, stated: "The ability to harness the power of the immune system to fight cancer has long been the desire of medical scientists. However, the potential of immunotherapy has not previously been convincingly demonstrated in the clinic. The Mirror Effect technology represents the first real promise for making immunotherapy into a clinical reality. What distinguishes the Mirror Effect from previous failed immunotherapy attempts is that the Mirror Effect mechanism has been reversed engineered from a mechanism already proven to be able to kill chemotherapy-resistant tumors. This mechanism creates a platform upon which we can build a pipeline of immunotherapy drug products. AlloStim is the first in this pipeline of new generation immunotherapy products."
About Immunovative, Inc.:
On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN's website at www.imun.com.
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL's website at: www.immunovative.co.il
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation, expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.
For more information please contact:
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
New York: +1-917-796-9926
- "All It Took Was One E-Mail to Larry," Says Former eBay Research Director As He Moves to Google
- Google Ramps Up Its Mobile Reach: Launches "Mobile Web Search"
- VoIP Update: Yahoo! Buys DialPad
- Ericsson + Napster = World's First "Wireless Digital Music" Brand
- Free Guest Passes for the SOA World Conference & Expo in NYC
- SYS-CON i-Technology Podcast August 30, 2005
- A Flair for Food - Health-Conscious Cooking Is This Chef's Cup Of Tea
- Sony PSP May Feature Porn
- Kapow Helps Seiko UK, Provides SMS Text-Alert Services
- South Korea is World's Largest Phisher
- Will the Mac OS Now Be Offered by Dell?
- UK Targeted for Trojan Attacks
- MAX 2006: Tracks Announced
- BT's "Fixed-Mobile" Phone Gives Callers the Best of Both Worlds
- MetaSolv to Host Provisioning Symposium in London